- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04915144
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overall, 200 subjects will be randomized (1:1 randomization ratio) to receive standard injected activities of 177Lu-DOTATOC PRRT or personalized injection of 177Lu-DOTATOC PRRT. Randomization will be stratified for grade and primary location.
Screening Phase: Subjects will be screened against the inclusion and exclusion criteria. Screening by SSR imaging will be completed to determine expression of SSR and feasibility of treatment by PRRT. Once eligibility has been confirmed they will be randomized. Subjects will undergo a physical exam, complete a medical history questionnaire, quality of life questionnaires, blood work, and a diagnostic CT.
Treatment Phase: During the treatment phase, subjects will undergo 4 cycles of treatment. Each treatment cycle will be followed by 2 dosimetry SPECT/CT scans on day 1 (18 - 32 hours after treatment administration) and day 2 (64 - 80h after treatment administration) After cycle 3 quality of life questionnaires will be completed again.
Follow up Phase: At the end of treatment or after discontinuation of any cause, subjects will be followed for 5 years to continue data collection for the other objectives. Objective tumour response will be assessed every 6 months by diagnostic CT according to the RECIST 1.1 criteria.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Administrative Research Manager
- Phone Number: 2818 604-877-6000
- Email: hayley.allan@bccancer.bc.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- BC Cancer
-
Contact:
- Administrative Research Manager
- Phone Number: 2818 604-877-6000
- Email: hayley.allan@bccancer.bc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to provide written informed consent
- Age greater than or equal to 19 years
- Biopsy-proven, well-differentiated grade 1 - 3 NET
- Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning
- Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma)
- Pulmonary NET, functioning and non-functioning
- Easter Cooperative Oncology Group (ECOG) ≤ 2
- Ki67 ≤ 55%
- Progressive disease demonstrated by RECIST 1.1 criteria within the 6 months preceding the study.
- Patients with other evidence of progressive disease that is not demonstrated on CT (like rising biomarkers) may be included, at the discretion of the Tumour Review Board.
- If response to other treatments is considered adequate according to other criteria, the Tumour Review Board may consider excluding the patient from participation in the study.
- Tumour Review Board confirmation of suitability to proceed to PRRT treatment and enrollment in this trial.
- Positive PET SSR imaging (Krenning score 2 or higher) in previous 6 months (68Ga-DOTATOC, 68Ga-DOTATATE, 18F-AmBF3-TATE). If PET SSR imaging is not available 111In-penetreotide scintigraphy (Octreotide scan) is acceptable.
- Adequate laboratory parameters within two weeks of enrollment
Kidneys
- Serum creatinine ≤ 150 µmol/L
- GFR ≥ 40 ml/min (using plasma clearance values)
Marrow
- Hemoglobin ≥ 80 g/L
- WBC ≥ 2 x 109/L
- Platelets ≥ 75 x 109/L
- Liver
- Total bilirubin ≤ 3 x upper limit of normal (ULN)
- ALT ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis
- Alkaline phosphatase ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis
- Subject's ability to comply with scheduled visits, treatment plans, laboratory tests, imaging tests, and other procedures required as detailed in the protocol.
Exclusion Criteria:
Women and men of childbearing potential Procreation
- Women: pregnancy test done before enrollment before each treatment cycle. And subject must use adequate contraception for the duration of therapy, be surgically sterile, or post-menopausal.
- Men: must be surgically sterile or use adequate contraception for the duration of the therapy.
- Patient with another non-cutaneous (excluding melanoma) active cancer requiring therapeutic intervention.
- Curative medical or surgical treatment, local liver embolization, or debulking are appropriate options.
- Life expectancy is less than 12 weeks.
- Radiotherapy to target lesions ≤ 12 weeks ago or to more than 25% of bone marrow.
- PRRT at any time prior to randomization in this study.
- Systemic therapy (chemotherapy) within 4 weeks of PRRT and other locoregional therapies (radioisotope, embolization) within 12 weeks prior to enrollment. Ongoing use of somatostatin analogs for control of symptoms is allowed.
- Known brain metastases (unless treated and stable for more than 3 months).
- Co-morbidities that could, in the opinion of the PI, interfere with safe delivery of PRRT (like urinary incontinence, psychiatric illness), uncontrolled congestive heart failure (NYHA II, III, IV)
- Breastfeeding (if patients elect to discontinue breast feeding, they can participate in the trial).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard PRRT
For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
|
Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
|
Experimental: Personalized PRRT
For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
|
Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine whether personalized 177Lu-DOTATOC PRRT reduces adverse events (AE).
Time Frame: 8 months
|
Frequency of AEs, will be compared between the two treatment arms.
|
8 months
|
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with RECIST criteria.
Time Frame: 12 months
|
PFS will be determined by RECIST1.1 criteria on serial CT, and analysed independently.
The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
|
12 months
|
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with ITMO criteria.
Time Frame: 12 months
|
PFS will be determined by biochemical criteria (ITMO) on serial CT, and analysed independently.
The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
|
12 months
|
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.
Time Frame: 12 months
|
PFS will be determined by Choi criteria on serial CT, and analysed independently.
The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine response rate of both treatment arms with RECIST1.1 criteria
Time Frame: 4 months
|
Response rate as determined by structural criteria RECIST1.1
|
4 months
|
Determine response rate of both treatment arms with Choi criteria
Time Frame: 4 months
|
Response rate as determined by structural criteria Choi.
|
4 months
|
Determine response rate of both treatment arms with ITMO criteria
Time Frame: 4 months
|
Response rate as determined by structural criteria biochemical markers (ITMO criteria) (chromogranin A, 24h urinary HIAA).
|
4 months
|
Quality of life (QoL) questionnaire scores (EORTC QLQ30) will be compared between the two treatment arms
Time Frame: 8 months
|
For QoL questionnaire scores (EORTC QLQ30) before, during, and after treatment
|
8 months
|
Quality of life (QoL) questionnaire scores (EORTC GINET21) will be compared between the two treatment arms
Time Frame: 8 months
|
For QoL questionnaire scores (EORTC GINET21) before, during, and after treatment
|
8 months
|
Quality of life (QoL) questionnaire scores (EQ-5D) will be compared between the two treatment arms
Time Frame: 8 months
|
For QoL questionnaire scores (EQ-5D) before, during, and after treatment
|
8 months
|
Correlation of QoL scores (EORTC QLQ30) to ctDNA
Time Frame: 8 months
|
To assess correlation of QoL scores (EORTC QLQ30) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
|
8 months
|
Correlation of QoL scores (EORTC GINET21) to ctDNA
Time Frame: 8 months
|
To assess correlation of QoL scores (EORTC GINET21) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
|
8 months
|
Correlation of QoL scores (EQ-5D) to ctDNA
Time Frame: 8 months
|
To assess correlation of QoL scores (EQ-5D) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
|
8 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS and QoL scores to ctDNA levels
Time Frame: 8 months
|
To assess correlation of PFS and QoL scores (EORTC QLQ30) to ctDNA levels (ctDNA allele frequency change from pre-treatment to on-treatment), the following tests will be used, Spearman correlation for quality of life and Kaplan- Meier curves stratified at a median for PFS.
|
8 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pancreatic Diseases
- Adenoma
- Pancreatic Neoplasms
- Adenoma, Islet Cell
- Carcinoma, Islet Cell
- Neuroendocrine Tumors
- Carcinoid Tumor
- Insulinoma
- Gastrinoma
- Molecular Mechanisms of Pharmacological Action
- Radiopharmaceuticals
- Edotreotide lutetium LU-177
Other Study ID Numbers
- H20-03401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Tumors
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingAdvanced Gastroenteropancreatic Neuroendocrine TumorChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdvanced Gastroenteropancreatic Neuroendocrine Tumor
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingNeuroendocrine Tumors,GastroenteropancreaticTaiwan
-
Grupo Espanol de Tumores NeuroendocrinosActive, not recruitingNeuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine TumorSpain
-
Australasian Gastro-Intestinal Trials GroupCompletedMidgut Neuroendocrine Tumours | Pancreatic Neuroendocrine TumoursAustralia
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
TaiRx, Inc.Active, not recruitingNeuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine NeoplasmTaiwan
-
Francesco De CobelliCompleted
-
Memorial Sloan Kettering Cancer CenterRecruitingNeuroendocrine Tumors | Liver-Dominant Metastatic Pancreatic Neuroendocrine TumorsUnited States
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
Clinical Trials on 177Lu-DOTATOC
-
University Hospital of FerraraRecruitingNeuroendocrine Tumors | Peptide Receptor Radionuclide Therapy (PRRT)Italy
-
Excel Diagnostics and Nuclear Oncology CenterWithdrawnNeuroendocrine Tumors | Pheochromocytoma | Paraganglioma | Unknown Primary Tumors | Pulmonary Neuroendocrine Neoplasm | Thymus Carcinoid | Neuroendocrine Skin Carcinoma | Neuroendocrine Breast Tumor | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Neoplasm of OvaryUnited States
-
University of Warmia and MazuryNational Center for Research and Development, Poland; Medical University of... and other collaboratorsUnknownNeuroendocrine TumorsPoland
-
Istituto Scientifico Romagnolo per lo Studio e...Not yet recruitingNeuroendocrine Tumors | Pheochromocytoma | Paraganglioma
-
Lund University HospitalActive, not recruitingNeuroendocrine TumorsSweden
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Paul Scherrer Institute (PSI)RecruitingNeuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)Switzerland
-
IpsenTerminatedGastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic TumoursUnited States, France, Belgium, Switzerland, Netherlands
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.Not yet recruitingAdenoid Cystic CarcinomaUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruiting
-
University Hospital, Basel, SwitzerlandSwiss Cancer LeagueRecruiting